Drug Trial Radar · NCT04886739
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
May 7, 2021
Primary completion
Dec 22, 2021
Study completion Dec 22, 2021
Sponsor
- Lead sponsor
- CAGE Bio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ethica Clinical Research Inc.
- First posted
- May 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic visits at Baseline (Day 0), and Weeks 2, 4, 8, and 12. Approximately 80 subjects will be enrolled and randomized at a 1:1 ratio to treatment with either CGB-400 Topical Gel (40%) BID or Vehicle Gel BID.
Conditions
- Rosacea
Interventions
CGB-400Drug
Topical gel
Vehicle GelDrug
Topical gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Inflammatory Lesion CountTime frame: Week 12
- Investigator Global Assessment (IGA)Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cage Bio Investigative Site 1
Fremont, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.